Home › Compare › REGRF vs ABBV

REGRF vs ABBV: Dividend Comparison 2026

REGRF yields 125000.00% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 REGRF wins by $4.4870750575756587e+27M in total portfolio value
10 years
REGRF
REGRF
● Live price
125000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.4870750575756587e+27M
Annual income
$4,480,024,748,164,424,300,000,000,000,000,000.00
Full REGRF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — REGRF vs ABBV

📍 REGRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodREGRFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, REGRF + ABBV cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
REGRF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

REGRF
Annual income on $10K today (after 15% tax)
$10,625,000.00/yr
After 10yr DRIP, annual income (after tax)
$3,808,021,035,939,760,400,000,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, REGRF beats the other by $3,808,021,035,939,760,400,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of REGRF + ABBV for your $10,000?

REGRF: 50%ABBV: 50%
100% ABBV50/50100% REGRF
Portfolio after 10yr
$2.2435375287878293e+27M
Annual income
$2,240,012,374,082,212,200,000,000,000,000,000.00/yr
Blended yield
99.84%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

REGRF
No analyst data
Altman Z
-45.2
Piotroski
2/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

REGRF buys
0
ABBV buys
0
No recent congressional trades found for REGRF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricREGRFABBV
Forward yield125000.00% ✓3.06%
Annual dividend / share$2.00$6.65 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6% ✓
Portfolio after 10y$4.4870750575756587e+27M$102.3K ✓
Annual income after 10y$4,480,024,748,164,424,300,000,000,000,000,000.00 ✓$24,771.77
Total dividends collected$4.486613188508161e+27M$61.0K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: REGRF vs ABBV ($10,000, DRIP)

YearREGRF PortfolioREGRF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$12,510,700$12,500,000.00$11,550$430.00+$12.50M → REGRF
2$14,628,690,187$14,615,303,738.32$13,472$627.96+$14628.68M → REGRF
3$15,987,233,390,392$15,971,580,691,892.04$15,906$926.08+$15987233.37M → REGRF
4$16,330,037,182,147,600$16,312,930,842,419,880.00$19,071$1,382.55+$16330037182.13M → REGRF
5$15,590,107,113,307,974,000$15,572,633,973,523,075,000.00$23,302$2,095.81+$15590107113307.95M → REGRF
6$13,911,095,050,184,500,000,000$13,894,413,635,573,263,000,000.00$29,150$3,237.93+$13911095050184500.00M → REGRF
7$11,601,822,386,032,217,000,000,000$11,586,937,514,328,520,000,000,000.00$37,536$5,121.41+$11601822386032216064.00M → REGRF
8$9,043,703,820,318,592,000,000,000,000$9,031,289,870,365,538,000,000,000,000.00$50,079$8,338.38+$9.043703820318592e+21M → REGRF
9$6,589,074,216,106,539,000,000,000,000,000$6,579,397,453,018,798,000,000,000,000,000.00$69,753$14,065.80+$6.589074216106539e+24M → REGRF
10$4,487,075,057,575,658,400,000,000,000,000,000$4,480,024,748,164,424,300,000,000,000,000,000.00$102,337$24,771.77+$4.4870750575756587e+27M → REGRF

REGRF vs ABBV: Complete Analysis 2026

REGRF — Stock

New World Solutions Inc. operates as a technology company. It provides exposure to various areas of decentralized finance and electric vehicle charging solutions to shareholders. The company was formerly known as Graph Blockchain Inc. and changed its name to New World Solutions Inc. New World Solutions Inc. is headquartered in Toronto, Canada. New World Solutions Inc. operates as a subsidiary of Bitnine Global Inc.

Full REGRF Calculator →

ABBV — Healthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this REGRF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

REGRF vs SCHDREGRF vs JEPIREGRF vs OREGRF vs KOREGRF vs MAINREGRF vs JNJREGRF vs MRKREGRF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.